Lab-on-chip market seen reaching $16.25 billion by 2030

The Business Research Company says the lab-on-chip market is set to grow from $8.85 billion in 2025 to $16.25 billion by 2030 as demand rises for faster diagnostics, personalized medicine and decentralized testing. North America led the market in 2025, while Asia-Pacific is projected to be the fastest-growing region.

Why it matters: - Lab-on-chip devices are gaining traction because they can speed up testing, cut reagent use and support more portable diagnostics. - The market’s growth reflects broader demand for personalized medicine, point-of-care testing and faster clinical results. - The shift could affect healthcare delivery in both advanced and resource-constrained settings, where compact testing tools can reduce turnaround times.

What happened: - The Business Research Company released a market study on the global lab-on-chip industry on Aug. 13, 2026. - The report pegs the market at $8.85 billion in 2025 and forecasts $10.02 billion in 2026. - The market is projected to reach $16.25 billion by 2030, implying a 12.8% CAGR from 2026 to 2030. - The study says North America held the largest market share in 2025. - The study says Asia-Pacific is expected to be the fastest-growing region during the forecast period. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - A free sample of the report is available here. - The full report is available here.

The details: - Lab-on-chip systems combine laboratory functions such as chemical analysis, biological assays and diagnostic tests on a miniaturized chip. - The devices handle very small fluid volumes with precision. - The technology is designed to improve speed, cost efficiency and throughput compared with conventional lab methods. - The report cites drivers behind recent growth, including microfluidics advances, higher diagnostic testing demand, more research funding, quicker clinical results and expansion in biotechnology research. - The forecast period also reflects growth in decentralized healthcare testing, more use in resource-limited settings, integration with digital health platforms, broader adoption in personalized diagnostics and a larger role in drug discovery. - Emerging trends include further miniaturization, more point-of-care testing, combining multiple lab functions on a single chip, expanded microfluidics use and rising demand for rapid diagnostics. - Personalized medicine is a major growth driver because genetic testing is making it easier to match therapies to individual patients. - Lab-on-chip devices can support personalized treatment by delivering rapid analyses of genetic and molecular data. - In February 2024, the Personalized Medicine Coalition said the FDA approved 16 new personalized therapies in 2023 for rare diseases, up from six in 2022.

Between the lines: - The forecast points to a market moving from specialized laboratory use toward broader clinical deployment. - Growth in decentralized testing suggests demand is shifting toward faster, nearer-to-patient diagnostics. - The regional outlook shows mature markets still dominate revenue, while newer healthcare systems may drive the fastest expansion.

What's next: - The market is expected to keep expanding as lab-on-chip devices become more integrated with digital health and personalized diagnostics. - The report highlights continued interest in miniaturization, multi-function chips and rapid-test applications as the next set of growth drivers. - The Business Research Company said its 2026 reports now include market attractiveness scoring, TAM analysis, company scoring matrices, forecasting dashboards, hotspot infographics and updated graphics and tables.

The bottom line: - Lab-on-chip technology is moving from a niche innovation to a broader diagnostics platform, and the market study expects strong growth through 2030.